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Abstract 
To investigate the involvement of opioids in the regulation of the reproductive axis, the 
opioid agonist loperamide was given via stomach tube to oestrus mares. In order to 
assess whether the opioid antagonist naltrexone is as effective as naloxone in over-
riding the inhibition of endogenous opioid pep tides on luteinizing hormone (LH) and 
follicle stimulating hormone (FSH) in the mare, naltrexone (NTX) was given to three 
dioestrus and seven anoestrus mares. Mares were given 20 and 40 mg NTX i.v .. In a 
third experiment, two anoestrus mares were given a dose of 80 mg NTX. Loperamide 
had no significant effect on either LH or FSH plasma concentrations in jugular blood. 
During dioestrus, both 20 and 40 mg NTX were effective in increasing LH and FSH 
plasma concentrations significantly. During anoestrus, two mares responded to the 20 
mg dose, while four responded to the 40 mg dose. One mare responded to the 80 mg 
dose. These results encourage the use of the opioid antagonist naltrexone to study 
opioid inhibition of LH and FSH in the mare. 
Keywords: opioids, loperamide, naltrexone, mare, reproduction. 
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Chapter One 
Introduction and Literature Review 
1.1 Introduction 
Opioids are known to influence a variety of physiological processes, including pain, 
respiration, blood pressure, behaviour, temperature and food intake. In particular, 
they have been shown to modify the secretion of several hypophyseal hormones 
including prolactin, adrenocorticotrophic hormone (ACTH), growth hormone, 
gonadotrophins, vasopressin and oxytocin. 
Several classes of opioid peptides (naturally occurring peptides with opiate-like 
biological properties) have been identified. These are the endorphins, enkephalins 
and dynorphins. Research since the seventies has suggested that the opioids, in 
particular the endorphins, are involved in the regulation of reproductive activity. 
During the reproductive life of all farm species, periods of anovulation occur as a 
result of suppressed levels of gonadotrophins, and failure of ovulation is a major 
cause of economic losses. The possibility exists that if opioids are involved in the 
regulation of gonadotrophin secretion, they may also be important in the control of 
ovulation and anovulation in domestic animals (Brookes et al., 1986). 
1.2 Endorphins 
1.2.1 Origin and localisation of J3-endorphin 
J3-Endorphin, a well characterised member of the endorphin family, is derived 
from a multifunctional prohormone known as pro-opiomeianocortin (POMC) 
(see Figure 1.1). POMC is synthesised in the brain, pituitary gland and 
placenta (Fer in et al., 1984). Upon cleavage, this 31 KDa glycoprotein yields 
ACTH (39 amino acid sequence) and J3-lipotrophin (J3-LPH) of 91 residues and 
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a 16 KDa molecular weight substance whose function is unknown. ~-LPH has 
no opiate-like activity, but contains in its 61-91 carboxy terminal end the 
sequence for ~-endorphin. · ~-Endorphin 1-31 is an active compound, but 
several other forms devoid of opioid activity have been identified, including 
~-endorphin 1-27 and acetylated ~-endorphin 1-31 (Zakarian and Smyth, 1982; 
reviewed by Jenkins & Grossman, 1992). 
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Figure 1.1 POMe and deriviates (from Mathews and van Holde, 1990). 
In the primate, immw10cytochemical studies have shown that central nervous 
system (eNS) fibres containing POMe-derived pep tides originate from 
neurons clustered in the arcuate region of the medial-basal hypothalamus 
(MBH). Such cell bodies are not observed at other eNS sites, suggesting that 
as in other species, this may be the principal site of synthesis within the brain 
(Ferin et al., 1984). Direct evidence in the rat that POMe biosynthesis occurs 
in the MBH is provided by the report that arcuate neurons contain both 
POMe mRNA and POMe peptides (Gee et al., 1983). The fibre system from 
these cell bodies is then distributed to multiple areas of the hypothalamus, as 
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well as the preoptic area, thalamus, stria terminalis, amygdala, and brainstem 
(Krieger et al., 1980). 
1.2.2 Site of ~-endorphin action 
The location of ~-endorphin and GnRH neurons in the hypothalamus 
provides anatomical evidence for interaction between the these two pep tides. 
Neuron to neuron interactions may occur within the arcuate region, an area in 
which cell bodies of both pep tides have been located, or within the median 
eminence which contains terminals for both GnRH and p-endorphin axons 
(reviewed by Ferin et al., 1984). 
1.2.3 Receptors for ~-endorphin 
Specific investigations have established that at least three opioid receptor 
subtypes are present: the 0-, 1(- and ~- receptors. Although the ~-receptor is 
highly sensitive to antagonism by naloxone, no specific ligand has been 
isolated, however p-endorphin probably fulfils this role (Howlett & Rees, 
1986). The majority of ~-receptors have been located in the limbic system 
which includes the hypothalamus (Goodman et al., 1980). The predominance 
of ~-receptor sites in the hypothalamus make p-endorphin a strong candidate 
for a role in the opioid control of endocrine secretion (Pfeiffer et al., 1987). 
1.3 Effects of opioid agonists in various species 
By definition, an opioid agonist occupies opioid receptors and stimulates them in a 
manner similar to the opioids. 
It is from research with morphine that the notion of opioids inhibiting 
gonadotrophin release has been put forward. Pang et al. (1972) reported that 
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morphine could block ovulation in the rat. Soon after, Santen et al. (1975) reported 
that women who were addicted to morphine had a high incidence of menstrual 
abnormalities, usually as a result of inadequate gonadotrophin secretion. Research 
with the rhesus monkey using morphine (Ferin et al., (1984); Kesner et al., 1986) 
supports the view that opioids modulate pulsatile gonadotrophin release by an 
action on the hypothalamic GnRH pulse generator. 
Dietz and Holtan (1985) studied the effects of morphine on LH serum concentrations 
in mares. Daily morphine treatment caused a tendency for LH concentrations to 
decrease, but not significantly. 
Loperamide hydrochloride (C29H33CIN202 .HCI) is an opioid agonist and has high 
specificity for ~-receptors. It is also non addictive, unlike the case of other agonists 
such as morphine. Because of its ability to reduce intestinal activity, loperamide is 
used extensively as an anti diarrhoeic agent in humans and other species including 
dogs and ca ts. 
1.4 Endorphin antagonists 
In order to test the hypothesis that endogenous opioids are involved in the control of 
gonadotrophin release, the specific opioid antagonists naloxone and naltrexone have 
been used in a number of different species. They act as competitive inhibitors and 
occupy the ~-receptor in preference to ~-endorphin. 
1.4.1 Naloxone 
Naloxone, normally used as naloxone hydrochloride (C19H21N04' HCI) (see 
Figure 1.2) is an opioid antagonist, and is the most frequently used 
compound in research on opioid action. 
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Figure 1.2 Structure of the opioid antagonist, naloxone. 
1.4.2 N altrexone 
Naltrexone, normally used as naltrexone hydrochloride (C2oH23N04' HCI) 
(see Figure 1.3), is an antagonist with a greater potency and its action is of a 
longer duration that is N-allyl congener naloxone. The cost of naltrexone is 
significantly less than that of naloxone, and the longer duration of the action 
encourages the exploration of its efficacy on simulating the effect of naloxone. 
Figure 1.3 Structure of the opioid antagonist, naltrexone. 
1.5 Effects of opioid antagonists in various species 
1.5.1 Human 
Quigley et al. (1980) reported that infusion of naloxone over a period of four 
hours resulted in an elevation of gonadotrophin levels and a restoration of 
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pulsatile luteinizing hormone (LH) release in some patients with secondary 
hypothalamic amenorrhoea. Also, Quigley and Yen (1980) reported that effect 
of the infusion of naloxone varied with stage of the menstrual cycle. 
Naloxone had no effect on LH release during the early follicular phase, 
whereas a significant increment was seen in both the late follicular and mid-
luteal phases of the cycle. The authors commented that the patterns of LH 
secretion were distinctly different between these two phases; late follicular 
subjects exhibited slow, progressive increases in LH, while prompt, episodic 
and quantitatively greater LH increments were evident in the mid-luteal 
phase. Blankstein et al. (1981) examined the effects of IV administration of 10 
mg naloxone in ten normally menstruating women. Whereas no LH response 
to naloxone was seen during the early follicular phase, significant LH 
increments were observed during the latter part. These observations suggest 
that opioids, endorphins in particular, are involved in the regulation of LH 
secretion and there is some involvement with gonadal steroids. 
It has been possible to elevate gonadotrophin levels and restore LH pulsatility 
over an extended period of 48 hours by the prolonged infusion of naloxone 
(Wildt et al., 1983). Because naloxone has a short response period, and is 
expensive to give over long periods of time, the orally active opioid 
antagonist naltrexone hydrochloride was administered daily, which resulted 
in restored ovulatory cycles in patients suffering from secondary 
hypothalamic amenorrhoea (Wildt and Leyendecker, 1987). The evidence for 
ovulation was based on the demonstration of follicular growth and corpus 
luteum formation by ultrasonography, a LH midcycle surge and a rise of 
progesterone. After discontinuation of the treatment, the women became 
amenorrhoeic again, and serum gonadotrophins and oestradiol declined to 
the low levels found before the administration of naltrexone. 
Wildt et al. (1993) continued these studies with naltrexone, and treated 121 
women suffering from hypothalamic ovarian failure with daily doses fro a 
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maximum of 100 weeks. The treatment was followed by an increase of 
gonadotrophins and a restored ovarian activity in approximately 70% of 
patients, with 22 pregnancies being achieved. This research suggests that an 
increase in opioid tone represents a major part of the neural mechanisms 
leading to the inhibition of GnRH release from hypothalamic neurons and 
thus to ovarian dysfunction in hypothalamic ovarian failure. These 
conclusions support the earlier findings of Rasmussen et aI. (1989), who fow1d 
that hypothalamic pulsatile GnRH release can be suppressed by an opioid 
receptor-mediated mechanism which is located in the MBH. The results from 
which this conclusion was based showed that the perfusion of the MBH, in 
vitro, with morphine suppressed the secretion of GnRH which was reversed 
by treatment with naloxone. 
In summary, treatment with naloxone or naltrexone increases plasma LH 
levels in women, suggesting that in humans, opioids tonically inhibit LH 
secretion. 
1.5.2 Non human primate 
There are several lines of evidence to support the conclusion that opioid 
peptides, and ~-endorphin in particular, participate in the control of 
gonadotrophin secretion in the female rhesus monkey. Ferin et al. (1984) 
fow1d that treatment with naloxone during the various stages of the oestrous 
cycle resulted in findings that are in agreement with the work of Quigley and 
Yen, that there is an interaction between opioids and LH release. They 
commented that this regulatory mechanism is complex and also involves 
gonadal steroids. As in humans, in the rhesus monkey LH secretion appears 
to be most suppressed by opioids during the luteal phase, at a time of 
elevated progesterone secretion. 
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1.5.3 Rat 
There is considerable evidence favouring the inhibitory role of endogenous 
opioid peptides in the control of LH in the rat (Piva et al., 1986). Treating rats 
with the opioid receptor antagonists naloxone and naltrexone increased 
plasma LH levels. And as is the case in primates, there is literature to suggest 
that gonadal steroids are involved in the inhibitory effects of opioids on LH 
secretion in rats (Allen & Kalra)986). 
1.5.4 Sheep 
Since opioid antagonists suppress tonic LH secretion in the ewe, with effects 
on both LH pulse amplitude and frequency, it can be inferred that opioids are 
involved in the regulation of LH secretion (Brooks et al., 1986). Currie et al. 
(1993) showed that when the median eminence in anoestrous ewes was 
perfused with naloxone, LH pulses were detected within 20 minutes in all 
ewes tested. They postulated from these results that a component of opioid-
suppression of LH secretion occurs at the median eminence. 
Conover et al. (1993) studied the in vivo release of GnRH from the posterior-
lateral ME. This was assessed by push-pull cannula (PPC) sampling before, 
during and after the infusion of doses of ~-endorphin or naloxone through the 
ppc. It was fow1d that after infusion of naloxone during the follicular phase, 
there was an increase in GnRH and LH secretion in a dose-dependent 
manner, and that the infusion of ~-endorphin through the PPC had an 
inhibitory effect on GnRH and LH. 
Weesner and Malven (1990) performed a series of experiments to determine if 
~-endorphin inhibits the release of LH in the central nervous system in sheep, 
and to identify the specific site of action. It was found that the intracerebral 
administration of naloxone into the mediobasal hypothalamus, the anterior 
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pituitary gland and the preoptic area of luteal phase ewes consistently 
increased LH release. 
1.5.5 Horse 
When the effects of endogenous opioid pep tides were first studied in the 
mare, early workers concluded that opioids were nill involved in seasonal 
breeding, because naloxone administration failed to generate a LH response 
during anoestrus (Sharp et al., 1985). The intravenous administration of 2 
mg/kg BW naloxone had no effect on the concentration of GnRH or LH in 
any of the twenty mares. In support of Sharp et al. 's conclusions, Dietz and 
Holtan (1985) reported that in anoestrus mares i.v. administration of 1 mg/kg 
BW naloxone did not increase LH secretion. 
Recent literature argues the opposite. Using the nonsurgical technique for 
collecting pituitary venous blood, developed by Irvine and Alexander (1986), 
Irvine et al. (1994) observed that the minimum dose able to increase in the 
secretion of GnRH in anoestrus mares was 0.04 mg/kg BW naloxone. This 
increased secretion of GnRH consequently induced an increase in LH and 
FSH plasma concentrations. In addition to measuring the gonadotrophins, 
Irvine et al. (1994) also monitored secretion of corticotrophin-releasing 
hormone (CRH), cortisol and ACTH. These hormones were measured 
because it has been shown that doses of 0.25 mg/kg naloxone activate the 
adrenal axis and thus cause an increase in plasma cortisol concentrations in 
humans (Grossman et al., 1986). It is postulated that increased adrenal axis 
activity, in particular the elevated CRH secretion, can inhibit GnRH release 
through both opioid and non-opioid pathways (Almeida et al., 1993; Rivest et 
aI.,1993). Only the higher 0.4 mg/kg dose of naloxone given by Irvine et al. 
(1994) stimulated cortisol (and CRH and ACTH) secretion, suggesting that the 
decreasing ability of naloxone to stimulate LH and FSH secretion in the 
anoestrus mares may be related to the activation of the adrenal axis, with the 
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resultant rise in CRR dampening the GnRH/FSH /LH responses. This 
potential interaction between these two axes could confound the results of 
experiments in which relatively large naloxone doses were given, as in 
research by Dietz and Holtan (1985) and Sharp et al. (1985). 
Administration of naloxone to mares at different stages of the oestrus cycle 
generates differing results, as in primates and rats. Behrens (et al., 1993) 
measured concentrations of LH and FSH in the plasma of follicular and luteal 
phase mares, before and after the administration of naloxone. During the 
follicular phase, mares did not respond to treatment with 300 mg 
(approximately 0.5 mg/kg BW) naloxone. However, during the luteal phase 
of the cycle, administration of 300 mg naloxone resulted in an increase in LH 
and FSH concentrations. These observations suggest that opioid peptides 
vary in their involvement of the regulation of gonadotrophin secretion 
during the oestrus cycle in horses. The inhibitory action of opioid systems on 
LH release during the luteal phase of the cycle seems to be a general finding 
as it is in agreement with other reports in horses (Turner et al., 1995) humans 
(Quigley and Yen, 1980; Blankstein et al., 1981), monkeys (Ferin et al., 1984) 
and sheep (Currie and Rawlings, 1987). The same would appear to be true for 
FSH as treatment of mares in the luteal phase with naloxone also induces a 
significant release of FSH, with changes in plasma FSH and LH 
concentrations occurring in parallel. 
Irvine et al. (1995) suggested that during various stages in the reproductive 
cycle the tone of opioid inhibition changes (the level of opioid tone is 
determined by the concentration of opioid peptides and their receptors). A 
dose of 0.1. mg/kg naloxone induced significantly higher FSH and LH 
plasma concentrations than smaller doses did (0.02 or 0.04 mg/kg) (Irvine et 
al., 1994). However, when a dose of 0.04 mg/kg was administered to 
dioestrus (luteal phase) mares, the response was similar to the anoestrus 
mares, who were given 0.1 mg/kg naloxone. Because anoestrus mares 
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required larger doses of naloxone than dioestrus mares to elicit a similar 
FSH/LH response, Irvine et al. (1995) suggested that the opioid tone is greater 
during anoestrus than dioestrus. Furthermore, they argue that the higher 
opioid tone maybe in part responsible for the absence of ovulation during this 
period. 
Naltrexone has been given to horses (Dodman et al., 1987), but not for 
studying the effects of opioids on the reproductive axis. 
1.6 Interactions between gonadal steroids and the opioid axis 
On the basis of literature reviewed above, it would appear that the opioid influence 
of LH release depends on gonadal steroids, especially progesterone. In 
ovariectomized women, naloxone influences LH release only after replacement with 
progesterone alone or combined with oestrogens. In species with a short follicular 
phase, such as rats or sheep, oestrogen may act synergistically with residual 
progesterone from the recently regressed corpus luteum in stimulating endogenous 
opioid systems. In mares, the period of high circulating oestrogen concentrations 
occurs at the beginning of oestrus, after luteolysis. An oestrogenic influence alone 
does not seen to activate opioid systems involved in the regulation of gonadotrophin 
release. 
It has been concluded by Behrens et al. (1993) that in mares, the negative feedback 
effects of progesterone, or progesterone and oestrogens, on gonadotrophin secretion 
is mediated at least in part by brain opioid systems. They suggested that the decline 
in circulating progesterone concentration after luteolysis terminates the opioid 
inhibition of gonadotrophin release. The subsequent increased gonadotrophin 
secretion favours follicular development and finally ovulation. 
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1.7 Summary 
~-Endorphin containing neurons are preferentially concentrated in areas of the brain 
known to be involved in regulation of gonadotrophin secretion. Naloxone and 
naltrexone, competitive inhibitors of opioids (also known as opioid antagonists), 
increase the release of gonadotrophins, suggesting tonic inhibition of gonadotrophin 
release by endogenous opioids. It has been suggested that the secretion of ~­
endorphin by the hypothalamus is modulated by ovarian steroid hormones, which 
also modulates gonadotrophin secretion. 
Naltrexone has been effective in treating women with amenorrhoea, inducing 
restoration of ovulatory cycles and enabling pregnancy to occur. Since naloxone can 
also induce a similar response in sufferers of this condition, it seems likely that the 
administration of naltrexone will give similar results as naloxone gives in mares. 
1.8 Objectives 
The objectives of the present study were to; 
• determine whether the opioid agonist loperamide is able to mimic opioid 
inhibition during the follicular phase of the oestrus cycle in the mare. 
• perform a pilot trial with the opioid antagonist naltrexone to determine whether 
this longer acting compound is able to stimulate FSH and LH secretion, and 
maintain its effects over a longer period than naloxone. 
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2.1 Materials 
Animals 
Chapter Two 
Materials and methods 
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Eight healthy standard-bred mares aged between four and eighteen years (Appendix 
I), weighing 450-550kg, were selected by criteria detailed below from the Lincoln 
University Equine Unit research herd of 21 mares. During the treatment period, the 
mares were kept unrestrained in a large outdoor yard to which they were accustomed, 
and at the end of each day were returned to their paddock. Mares had ad lib access to 
water and hay. 
At the beginning of each trial, each mare was led into the crush, a patch of hair clipped 
off the neck if necessary, and a cannula (Angiocath, 16 gauge, 5.25 in; Deseret Co., 
Sandy, UT, USA) was inserted into the right jugular vein (see Figure I), with O.5mL 
EDTA injected after each sample was taken (to prevent blood clotting in the calU1ula). 
Plate 2.1 Cannula in right jugular vein. 
14 
Opioid agonist - Loperamide hydrochloride 
Loperamide hydrochloride (Imodium, Janssen Cilag, Belgium) was given to the mares 
via a stomach tube in solution. The solution was contained 100mg of loperamide (50 
capsules each containing 2mg were used) was added to 15mL ETOH and made into a 
slurry by mixing, then made up to 200mL with hot water (approximately 50°C). This 
dose was based upon the research of Auernhammer et al. (1992) who found that a dose 
of 16 mg of loperamide to humans was able to reduce ACTH secretion (16mg in 75kg 
human = 100mg in 500kg horse) . 
Opioid antagonist - Naltrexone hydrochloride 
Dodman et al. (1987) saw a similar response in horses to 0.04 mg/kg of naltrexone and 
0.04mg/kg of naloxone, Turner et al., (1995) found that a dose of 0.04 mg/kg of 
naloxone induced an increase of FSH and LH. Therefore, a minimum dose of 0.04 
mg/kg naltrexone (NTX) was given. NTX (Sigma Chemical Co., St Louis, MO, USA) 
was dissolved in 10mL of sterile saline and administered within 5 hours. 
2.2 Experimental protocol 
The experimental protocol was approved by the 1995 Lincoln University Ethics 
Committee. 
Mares were teased by the stallion at various stages of each experiment to determine 
whether sexual behaviour was affected by the treatments, as it has been noted that 
during experiments with naloxone, anoestrus mares have shown some signs of oestrus 
behaviour, i.e. clitoral winking (Turner, JE pers. comm.1995). 
Experiment 1 - Aim: to determine whether loperamide treatment changes LH and lor FSH 
plasma concentrations in oestrus mares. 
Three mares were determined to be in oestrus when they showed strong oestrus 
behaviour to the teaser stallion and by the presence of a mature follicle in. the ovary 
(determined by palpation per rectum (plate 2.1)). Once the cannula was in position, 
blood samples were taken from the cannula every 15 minutes. After an hour, each of 
the three mares received 50mg loperamide in solution (200mL) by stomach tube, and 
sampling continued every 15 minutes for 6 hours. 
Plate 2.2 Determination of ovarian dynamics by rectal palpation. 
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Experiment 2. Aim: to determine whether naltrexone treatment causes a change in LH and/or 
FSH plasma concentrations in dioestrus mares. 
Three mares were determined to be dioestrus when progesterone concentrations were 
above 2ng/mL, and by following the pattern of ovarian activity for the past four cycles 
it was possible to determine when each mare was between oestrus cycles. Sampling 
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began at -60, -30 and 0 minutes before 20mg NTX administration. Blood sampling 
continued every 15 minutes for 4 hours, after which 40mg of NTX was administered iv 
through the cannula, and collection of blood samples continued at 15 minute intervals 
for another 4 hours. 
Experiment 3. Aim: to determine whether naltrexone treatment causes a change in LH and/or 
FSH plasma concentrations in anoestrus mares. 
Three mares were determined to be acyclic by the following criteria; 
• small and hard ovaries determined by palpation per rectum, 
• lack of oestrus behaviour for at least 4 weeks prior to the experiment. 
There were three parts to experiment 3. The aims of these experiments were the same, 
but the experimental protocol differed slightly with each one. 
Experiment 3a. 
The experiment was performed over two days with one day being a control bleed, and 
the other for NTX treatment (refer to Table 2.1). 
MareR MareGR MareT 
Day 1 Naltrexone Naltrexone Control 
Day 2 Control Control Naltrexone 
Table 2.1 Regime for experiment 3a. 
Sampling began at -30, -15 and 0 minutes before administration of 20mg NTX i.v. 
through the jugular ca1U1ula, with 15 minute sampling continued for four hours after 
NTX treatment, after which 40mg NTX was given in the same manner. 
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Experiment 3b. 
Four mares were determined to be anoestrus by the criteria stated previously. On day 
one, sampling began -30, -15 and 0 minutes before iv administration of 20mg NTX. 
Collection of blood samples continued at fifteen minute intervals for four hours. On 
day two, the mares were administered 40mg of NTX, with the sampling procedure 
being the same as for day one. 
Experiment 3c. 
Two of the mares used in experiment 3b (who remained in anoestrus) were given a 
dose of 80mg of NTX in 10mL sterile saline after samples were taken at -30, -15 and 0 
minutes before NTX injection. Collection of blood samples continued at 15 minute 
intervals for four hours. 
Sample handling 
Blood samples (5mL) were collected into polystyrene tubes containing 10mg sodium 
EDTA, and stored on ice until centrifugation. Plasma was separated by centrifugation 
for 5 minutes at 2,500 r.p.m within one hour of collection and stored at -20°C until 
assayed. 
Assays 
All samples were assayed in duplicate for LH and FSH using previously validated 
radioimmunoassays (FSH: Irvine & Alexander, 1993: LH: Shand et al., 1991). Plasma 
samples were assayed for progesterone by an enzyme-linked immunosorbent assay 
(ELISA) using microtitre plates (Elder et al., 1987). 
Statistical analysis 
Student's paired t-test was used to test whether the pre-treatment samples and the 
samples taken 1.5 h after the administration of the opioid agonist were significantly 
different. The Student's paired t-test was also used to test whether NTX induced a 
significant response. The three samples that were tested against the pre-treatment 
samples depended on whether there was an increase in gonadotrophin plasma 
concentrations. In most cases, it was the 30, 45 and 1 h post treatment samples. 
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In two of the experiments the 40 mg NTX dose was given four hours after the 20mg 
dose. If the gonadotrophin concentrations had not returned to pre-treatment values, 
the rate of decline of the gonadotrophins from the blood was estimated. This was 
calculated by taking a line of best fit that extended down towards the x-axis, and using 
regression analysis to calculate what the gonadotrophin concentrations would have 
been if the 40mg dose had not been given. The concentrations of the gonadotrophins 
present after the treatment were subtracted from the values from the line of best fit. 
The Student's paired t-test was performed to determine whether increases in LH and 
FSH plasma concentrations were significant when compared with the pre-treatment 
concentrations. 
Chapter Three 
Results 
3.1 Effect of loperamide on LH and FSH plasma concentrations in 
oestrus mares. 
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There was no significant difference in plasma LH or FSH concentrations between the 
pre-treatment samples and samples taken 1.5 h after loperamide administration (see 
Table 3.1, Figures 3.1, 3.2 and 3.3). Mares continued to display oestrus behaviour 
during the experimental period (Plate 3.1). No change in faecal consistency was noted. 
Plate 3.1 Mares showing oestrus behaviour to the teaser stallion. 
pre-trt post-trt 
Mare Gn mean mean p-value 
E ILH 4.95 5.48 0.690 
FSH 1.28 1.31 0.288 
Y LH 20.42 19.68 0.518 
FSH 3.26 3.07 0.186 
GN LH 9.73 10.69 0.100 
FSH 1.25 1.37 0.166 
Table 3.1 p-values from Student's t-test of pre and post samples after loperamide treatment to oestrus 
mares. 
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Figure 3.1 Plasma concentrations of LH and FSH in plasma during the oestrus period in mare 
E (loperarnide given at time 0). 
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Figure 3.2 Plasma concentrations of LH and FSH during the oestrus period in mare Y 
(loperarnide given at time 0) . 
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Figure 3.3 Plasma concentrations of LH and FSH during the oestrus period in mare.GN 
(loperamide given at time 0). 
Table 3.2 shows the estimated stages of oestrus of the three mares used. 
Mare Day of oestrus 
E 2 
Y 4 
GN 4 
Table 3.2 Estimated stage of oestrus of the three mares in experiment 1. 
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3.2 Effect of naltrexone on LH and FSH plasma concentrations in 
dioestrus mares. 
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As can be seen from Table 3.3 (and Figures 3.4, 3.5 and 3.6), all mares had a significant 
increase in both gonadotrophins following NTX treatment. The exception was mare 
GN who began an endogenous pulse during the pre-treatment sampling period (Figure 
3.6) and so could did not respond to the 20 mg dose. 
Mare Gn Ipre-trt Ipost-20mg 20mgNTX Ipost-40mg 40mgNTX 
Day of dioestrus mean mean P-value mean P-value 
E LH 1.03 8.95 0.0003*** 6.38 0.015** 
day 6 FSH 4.85 14.41 0.0003*** 7.23 0.008*** 
Y LH 3.88 7.92 0.015** 8.52 0.005*** 
day 10 FSH 3.41 6.51 0.019** 6.02 0.035** 
GN LH 4.31 NA NA 8.94 0.004*** 
day 6 FSH 3.50 NA NA 4.79 0.01 ** 
Table 3.3 Dioestrus mares P-values from Student's paired t-test, and stage of dioestrus. Since 
mare GN began an endogenous pulse during the pre-treatment period, the pre-treatment mean 
was calculated from samples taken before pulse began for analysis of response to 40 mg dose. 
*** = significant at the 1% level, ** = significant at the 5% level, NA = not analysed. 
Because mare GN showed an endogenous pulse in the pre-treatment period, these data 
from the 20 mg dose were not included for statistical analysis. The magnitude of the 
response to 20 mg of naltrexone differed between the mares. Mare E's FSH levels 
increased at least three-fold after naltrexone treatment, while those of Mare Y doubled. 
The FSH pre-treatment levels were very similar. 
The increase in FSH plasma concentrations 1.5 h after NTX treatment suggest that a 
second pulse of gonadotrophin release had occurred (Figure 3.5). 
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Figure 3.4 Plasma concentrations of LH and FSH before and after 20 and 40 mg NTX during 
dioestrus (Mare E). 40 mg NTX administered at 4 h. 
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Figure 3.5 Concentration of LH and FSH before and after 20 and 40 mg of NIX during 
dioestrus (Mare Y). 40 mg given 4 hours after the 20 mg dose. 
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Figure 3.6 Concentration of LH and FSH before and after 20 and 40 mg of NIX during 
dioestrus (Mare GN). 40 mg given at 4 h. Levels of FSH and LH rise before treatment (between 
-0.5 and Oh), indicating an endogenous pulse. 
3.3 Effect of naltrexone on LH and FSH plasma concentrations in 
anoestrus mares 
3.3.1 Experiment 3a 
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As shown in Table 3.4, Mare T showed a significant increase in LH and FSH plasma 
concentrations after treatment with 20 mg and 40 mg NTX (Figure 3.9), while there was 
no significant difference between the pre- and post-treatment samples in Mares GR or 
R. 
Mare Gn pre-trt post 20mg 20mgNTX post 40mg 40mgNTX 
mean mean p-values mean p-values 
GR LH 1.19 1.47 0.304 1.44 0.293 
FSH 1.02 0.94 0.104 0.73 0.208 
R LH 1.24 1.19 0.588 NA NA 
FSH 6.24 5.74 0.213 NA NA 
T LH 0.74 3.99 0.001 *** 3.55 0.001 *** 
FSH 1.79 37.29 0.003*** 19.76 0.001*** 
Table 3.4 P-values from Student's paired t-test of the first anoestrus experimental results. 
*** = significant at 1 % level, NA = not analysed. 
Figures 3.7, 3.8 and 3.9 show changes in gonadotrophin secretion in the three mares 
after NTX doses of 20 and 40 mg, and the control day bleed. When comparing the 
control day bleed with the treatment day, it is apparent that the pattern of LH and FSH 
in mare GR or R did not vary. Mare R had an endogenous pulse after the 5 h sample 
was taken. 
Mare T had two increases in both LH and FSH plasma concentrations after the 20 mg 
NTX (Figure 3.9). 
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Figure 3.7 Plasma concentrations of LH and FSH during control day and before and after 20 
and 40 mg NTX (mare GR). 
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Figure 3.8 Plasma concentrations of LH and FSH during control day before and after 20 mg 
and 40 mg NTX (Mare R). Note increases in LH and FSH concentrations after 3.5 hours (0,5 h 
before 40 mg NTX dose), indicating an endogenous pulse. 
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Figure 3.9 Plasma concentrations of LH and FSH during control bleed and before and after 20 
and 40 mg NTX (mare T). 
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3.3.2 Experiment 3b 
Table 3.5 shows the pre- and post-treatment means and p-values from the second 
anoestrus experiment (3b). Only Mare Y had a significant increase in both FSH and LH 
plasma concentrations in response to the 20 mg dose (Figure 3.16). Three mares (N, GN 
and Y) had significant increases in LH and FSH plasma concentrations in response to 
the 40 mg dose, while mare P did not respond to either dose. Pre-treatment 
concentrations of plasma FSH are very high in mare N (Figure 3.10). The decline in 
plasma concentrations that occurred during the sampling period indicates that an 
endogenous pulse occurred before the sampling began, so these data were not 
analysed. 
Mare Gn pre-trt post 20mg 20mgNTX pre-trt post 40mg 40mgNTX 
mean mean p-value mean mean Q-value 
N LH 1.82 1.72 NA 1.28 2.04 0.005*** 
FSH 17.47 16.23 NA 8.27 26.94 0.015** 
P LH 0.83 0.82 0.254 0.86 0.75 0.276 
FSH 3.81 4.43 0.007 5.46 5.44 0.967 
GN LH 1.12 1.24 0.435 0.88 1.39 0.008*** 
FSH 3.73 4.44 0.129 4.00 13.54 0.004*** 
Y LH 1.34 2.60 0.012** 1.91 2.71 0.011 ** 
FSH 4.66 13.28 0.004*** 6.48 9.53 0.009*** 
Table 3.5 P-values from Student's pa:ired t-test of the second anoestrus experimental results. 
***= significant at 1 % level, ** =significant at the 5% level, NA = not analysed. 
As can be seen in Figure 3.16 there is a second increase in plasma concentrations of LH 
and FSH 2.25 h after NTX treatment. 
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Figure 3.10 Plasma concentrations of LH and FSH before and after 20 mg NTX (mare N) 
during the second anoestrus experiment. 
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Figure 3.11 Plasma concentrations of LH and FSH before and after 40 mg NTX (mare N) 
during the second anoestrus experiment. FSH concentrations increase 0.25 h before NTX 
administration, indicating an endogenous pulse was beginning. 
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Figure 3.12 Plasma concentrations of LH and FSH before and after 20 mg NTX (mare P) 
during the second anoestrus experiment. 
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Figure 3.13 Plasma concentrations of LH and FSH before and after 40 mg NTX (mare P) 
during the second anoestrus experiment. 
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Figure 3.14 Plasma concentrations of LH and FSH before and after 20 mg NTX (mare GN) 
during the second anoestrus experiment. 
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Figure 3.15 Plasma concentrations of LH and FSH before and after 40 mg NTX (mare GN) 
during the second anoestrus experiment. 
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Figure 3.16 Plasma concentrations of LH and FSH before and after 20 mg NTX (mare Y) in 2nd 
anoestrus experiment. 
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Figure 3.17 Plasma concentrations of LH and FSH before and after 40 mg NTX (mare Y) in the 
second anoestrus experiment. 
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3.3.3 Experiment 3c 
Table 3.6 shows the Student's t-test results from the comparison of the pre- and post-
treatment samples from the third anoestrus experiment (3c). Only mare N responded 
significantly to the 80 mg dose of NTX. Figures 3.18 and 3.19 show the changes in LH 
and FSH plasma concentrations before and after treatment with 80 mg NTX. 
Mare Gn pre-trt post 80mg 80mgNTX 
mean mean P-values 
GN LH 1.43 1.61 0.257 
FSH 14.95 12.83 0.243 
~ LH 0.69 1.48 0.006*** 
FSH 6.86 15.61 0.001 *** 
Table 3.6 P-values from Student's paired t-test of the third anoestrus experimental results. 
*** = significant at 1 % level. 
From Figure 3.18 it can be seen that the pre-treatment plasma concentrations of LH and 
FSH are higher than mare N, suggesting that mare GN had begun an endogenous pulse 
before sampling began. 
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Figure 3.18 Plasma concentrations of LH and FSH before and after 80mg NTX during anoestrus (mare 
GN). 
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Figure 3.19 Plasma concentrations of LH and FSH before and after 80mg NTX during 
anoestrus (mare N). 
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Chapter Four 
Discussion 
4.1 Effect of loperamide treatment during oestrus 
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Treatment with the opioid agonist loperamide did not result in a decrease in plasma 
concentrations of LH and FSH in the oestrus mare. There are several possible reasons 
why loperamide did not mimic the proposed opioid inhibition of gonadotrophin 
secretion. 
Firstly, because loperamide is a non-addictive opioid agonist, it may not be able to 
cross the blood-brain barrier to agonistically stimulate the Il-receptors located on the 
surface of GnRH neurons in the arcuate area of the hypothalamus. Several reports 
show that loperamide penetrates the blood-brain barrier poorly in rats, and that it lacks 
any central opiate-like effects in man (Schuermans et al. 1974; Stahl et al. 1977, cited in 
Auernhammer et al. 1992). However, since loperamide has a high affinity for 11-
receptors, and there is a high concentration of Il-receptors in the hypothalamus, it is 
possible that loperamide is can cross the blood brain barrier. Results from this 
experiment suggest that loperamide did not cross the blood-brain barrier to stimulate 
receptors located in the arcuate region of the hypothalamus. However, since the 
median eminence is located outside the blood brain barrier, it may be that there were 
insufficient quantities of the agoinst to stimulate the receptors. 
A second possibility is that the amount of loperamide given in this experiment was 
inadequate to induce a response. The dosage given to the mares was based upon 
research performed with humans (Auenmammer et al. 1992), and it is not known 
whether this compound is absorbed equally well from the digestive tracts of horses and 
humans. While the dose given in these experiments was the same as that used by 
Roberts & Argenzio (who used ponies), it suggests that for studying effects of agonists 
in higher areas, such as the eNS, a larger dose of loperamide maybe required. 
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Another reason for the failure of loperamide to alter gonadotrophin concentration 
could be that the method of administration was unsuitable. Loperamide was 
administered via a stomach tube, and all three mares were disturbed by this procedure 
(they became unsettled and resisted the stomach tube being put in place). This distress 
may have altered the effectiveness of the drug. Gut motility and absorption could have 
decreased, which in turn would reduce the concentration of loperamide available for 
agonising the Il-receptors in the mediobasal hypothalamus/median eminence. 
Another explanation for the results is that loperamide bound to the Il-receptors in the 
intestinal tract in preference to those receptors located elsewhere. 
4.2 Effect of naltrexone treatment during dioestrus 
During dioestrus, the intravenous administration of 20 and 40 mg of the opioid 
antagonist naltrexone (NTX) induced a significant increase in gonadotrophin plasma 
concentrations in all mares. The only exception was mare GN, who began an 
endogenous pulse before the administration of 20mg NTX, and was therefore unable to 
respond to that treatment. 
The LH and FSH response to NTX treatment during dioestrus is consistent with reports 
on the mares with naloxone by others (Brehens et al., 1993; Turner et al., 1995). Irvine's 
group saw an increase in LH and FSH plasma concentrations within 30 minutes of 
naloxone administration. In the present experiment, a peak of gonadotrophin plasma 
concentrations was also seen 30 minutes after NTX aministration. 
One of the objectives of these experiments was to determine whether NTX was able to 
block opioid inihibition for long enough to allow pulses of LH and FSH to be 
displayed. Of the three mares in this experiment, mare Y had a second increase in LH 
and FSH plasma concentrations 1.5 h after NTX, which could have been caused by the 
administrartion of NTX. Mare Y was at a different stage of dioestrus (day 10) in 
comparison with the other mares who were day 6, this may by the reason for the 
difference in the type of response to NTX. 
The results from this experiment support the theory that opioids are involved in the 
inhibition of gonadotrophin secretion during the luteal or dioestrus phase of the 
ovulatory cycle. These results also suggest that NTX is as effective as naloxone in 
stimulating an increase in plasma concentrations of LH and FSH, and may allow a 
certain degree of pulsatility in the type of response. 
4.3 Effect of naltrexone treatment during anoestrus 
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Of the three mares involved in the first anoestrus experiment, only one mare (T) 
responded to both 20 and 40mg NTX. In addition to this intial response, mare T had a 
further increase in LH and FSH plasma concentrations two hours after the 20mg dose, 
which implies that NTX may have had a long term effect on the Il-receptors, allowing 
the endogenous activity of the GnRH pulse generator to be displayed. Mare GR did 
not respond to either 20 or 40 mg NTX. These results suggest that the level of opioid 
tone may vary between individual mares, such that mare T was not as "deeply 
anoestrus" as mare GR. Mare R had an endogenous pulse prior to administration of 40 
mg NTX, so that no response to NTX was possible. 
Results from the second anoestrus experiment support the findings of Aurich et al. 
(1993) and Irvine et al. (1994), which propose that opioids inhibit gonadotrophin 
secretion in anoestrus mares. While only one mare (Y) responded to 20 mg NTX, three 
of the four mares in this experiment showed a significant increase in both 
gonadotrophins after the 40mg dose. The changes in plasma concentrations of FSH and 
LH after mare Y was given 20 mg NTX suggest that a second pulse occurred, but it is 
not possiblt to determine whether this was due to NTX treatment. Results indicate that 
mare N had an endogenous pulse before the experiment began on day I, so was unable 
to respond to NTX administration. Mare P did not respond to either dose, which may 
suggest that this mare was very deeply anoestrus. 
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Having evaluated the results of the first and second anoestrus experiments, it was 
decided to increase the dose of NTX given to anoestrus mares, to determine whether 
the dose of naltrexone given was adequate to produce a response, since several mares 
did not respond to either dose. Mare N showed a significant increase in both LH and 
FSH plasma concentrations. Mare GN's pre-treatment levels of FSH were much higher 
than other anoestrus mares, it seems that mare GN was undergoing an endogenous 
pulse during the sampling period, reducing the ability of the reproductive axis to 
respond to the antagonism of opioid inhibition. 
In cyclic mares (Brehens et al. 1993; Irvine et al. 1993), and in females of other species 
(Quigley & Yen, 1980, Currie & Rawlings, 1987), the opioid inhibition of LH release 
seems to depend on the presence of progesterone. Results of this study, and those of 
other researchers (Aurich et al., 1994; Turner et al. 1995), suggest that ovarian steroids 
may differ in their effect of opioid regulation of LH release in anoestrus and oestrus 
mares. During the anoestrus period, there is little ovarian activity and therefore only 
low concentrations of the gonadal steroids oestradiol and progesterone would be 
present. It could be that opioid inhibition of LH and FSH during anoestrus is activated 
independently of gonadal steroids. In support of this, Aurich & Aurich (1995) recently 
reported from research with ovariectomised mares whic showed that opioid systems 
inhibit LH release independently from ovarian factors. 
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Chapter Five 
Conclusions 
From the results attained from this study it seems that loperamide is unsuitable for the 
purpose of examining the effects of opioids on gonadotrophin secretion in oestrus 
mares. Possible reasons for this include; 
• loperamide unable to cross the blood-brain barrier to act upon the ).l-receptors 
located in the arcuate region; 
• inadequate dose of loperamide was used; 
• method of administration was inappropriate. 
NTX has been used in preference to naloxone in humans (Wildt et al., 1993) and has 
prolonged effects on the ).l-receptor. It was hypothesised that NTX would allow plasma 
gonadotrophin concentrations to remain higher than when naloxone was given, 
possibly allowing pulsatile activity to be seen. 
When given to dioestrus mares, NTX stimulated an increase in all mares that could 
respond. The duration of elevated LH and FSH plasma concentrations was greater 
when treated with NTX than when treated with naloxone (unpublished results, Irvine 
1995). Additionally, changes in plasma LH and FSH concentrations after NTX 
treatment indicated pulsatile activity in one of the three mares. 
The use of NTX in anoestrus mares gave varied results, as two mares did not respond 
to NTX at all. Several mares had endogenous peaks prior to sampling or treatment, 
which prevented them from being able to respond to treatment. However, given the 
number of animals used, these results are not discouraging. After NTX, plasma 
concentrations of LH and FSH were elevated over a greater period than when naloxone 
was administered. Changes in plasma LH and FSH concentrations after NTX treatment 
suggest that the pulse generator was activated in two mares (T and Y). 
While NTX treatment did not induce pulsatile gonadotrophin secretion in all mares, 
responses to NTX treatment in dioestrus and anoestrus mares suggests that NTX may 
be used instead of naloxone to study how opioids are involved in the activity of the 
reproductive axis. 
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Appendix 
The names and ages of mares used in these experiments are as follows; 
Mare Age (years) 
E (Ellen) 11 
GN (Goodnight Nurse) 9 
GR (Greta Rae) 5 
N (No No) 7 
P (Pontoon) 18 
R (Rosie) 4 
T (Trixie) 6 
